地氯雷他定治疗慢性特发性荨麻疹:评估临床疗效。
文章的细节
-
引用
复制到剪贴板 -
DuBuske L
地氯雷他定治疗慢性特发性荨麻疹:评估临床疗效。
是中国新药杂志。2007;8 (5):271 - 83。
- PubMed ID
-
17902729 (在PubMed]
- 文摘
-
慢性特发性荨麻疹(CIU)是一种苦难,大大限制了病人的日常活动和干扰睡眠。临床研究表明,组胺H1-receptor拮抗剂(抗组胺药)是高度有效的抑制与CIU相关荨麻疹/水疱和瘙痒,以及改善患者的生活质量。地氯雷他定是一个快速,每日一次,nonsedating选择性H1-receptor拮抗剂/逆受体激动剂与证明CIU患者的临床疗效。它体内H1受体结合亲和力的10 - 20倍氯雷他定,其母体化合物和52 - 194倍西替利嗪的H1受体结合亲和力,ebastine,氯雷他定、盐酸非索非那定。地氯雷他定口服后显示线性药物动力学。年龄和性别没有明显影响药物的代谢和消除,和食品并不影响其生物利用度或吸收。地氯雷他定也通过机制发挥抗炎作用独立于H1-receptor对抗。结果随机、双盲、安慰剂对照研究6周的时间在成人和青少年严重CIU表明地氯雷他定大大减少瘙痒症的严重程度,减少荨麻疹的数量和规模,并提高disease-impaired睡眠和日常活动。改进后被指出单一剂量的地氯雷他定,保持超过6周的治疗。地氯雷他定是安全和耐受性良好CIU患者的临床试验。 The adverse effect profile of desloratadine in adults, as well as in children aged from 6 months to 11 years, is comparable to that of placebo. Evaluations of cognitive and psychomotor performance in adults indicate no impairment of function with dosages of desloratadine 5 mg/day. In conclusion, desloratadine is an important therapeutic option for prompt and enduring symptom relief in patients with moderate-to-severe CIU. In addition to efficacy and safety, desloratadine affords a convenient administration regimen, rapid onset of action, and an absence of drug-drug or drug-food interactions. Other important prescribing considerations are that, unlike all first-generation and some second-generation antihistamines, desloratadine is nonsedating at its clinically approved dosage and does not impair psychomotor function.